Profile data is unavailable for this security.
About the company
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
- Revenue in USD (TTM)524.07m
- Net income in USD-417.27m
- Incorporated2009
- Employees702.00
- LocationApellis Pharmaceuticals Inc100 Fifth AvenueWALTHAM 02451United StatesUSA
- Phone+1 (617) 977-5700
- Fax+1 (302) 655-5049
- Websitehttps://apellis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunovant Inc | 0.00 | -259.34m | 3.71bn | 207.00 | -- | 5.98 | -- | -- | -1.89 | -1.89 | 0.00 | 4.24 | 0.00 | -- | -- | 0.00 | -48.37 | -- | -52.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.85bn | 271.00 | 27.63 | 2.34 | 23.77 | 3.04 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
| Alkermes Plc | 1.73bn | 599.95m | 3.96bn | 2.10k | 6.68 | 3.16 | 5.96 | 2.29 | 3.50 | 2.53 | 10.05 | 7.42 | 0.8532 | 1.32 | 5.81 | 821,991.40 | 29.65 | 1.34 | 38.77 | 1.74 | 85.31 | 83.32 | 34.76 | 2.12 | 2.77 | -- | 0.1878 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Hims & Hers Health Inc | 959.40m | -2.35m | 4.17bn | 1.05k | -- | 12.09 | 518.28 | 4.35 | -0.0145 | -0.0145 | 4.46 | 1.61 | 2.33 | 6.68 | 176.36 | 917,209.40 | -0.5704 | -- | -0.6968 | -- | 82.41 | -- | -0.245 | -- | 2.48 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
| Alvotech SA | 114.39m | -494.28m | 4.20bn | 999.00 | -- | -- | -- | 36.73 | -2.05 | -2.05 | 0.4909 | -2.47 | 0.117 | 1.69 | 1.97 | 114,507.50 | -50.54 | -- | -63.82 | -- | -23.89 | -- | -432.09 | -- | 0.8107 | -1.26 | 2.49 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Nuvalent Inc | 0.00 | -145.51m | 4.24bn | 106.00 | -- | 6.27 | -- | -- | -2.41 | -2.41 | 0.00 | 10.47 | 0.00 | -- | -- | 0.00 | -24.88 | -- | -26.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Immunitybio Inc | 302.00k | -600.96m | 4.44bn | 628.00 | -- | -- | -- | 14,701.54 | -1.05 | -1.05 | 0.0005 | -1.02 | 0.0008 | -- | 0.1677 | 480.89 | -161.65 | -112.76 | -946.50 | -316.07 | -- | -- | -199,138.70 | -37,700.74 | -- | -1.92 | 5.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Krystal Biotech Inc | 95.95m | 57.16m | 4.57bn | 229.00 | 85.04 | 5.71 | 72.06 | 47.64 | 1.88 | 1.88 | 3.38 | 28.02 | 0.1385 | -- | -- | 418,991.30 | 8.25 | -11.50 | 8.78 | -12.01 | 94.25 | -- | 59.57 | -492.85 | 12.42 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Apellis Pharmaceuticals Inc | 524.07m | -417.27m | 4.76bn | 702.00 | -- | 17.85 | -- | 9.09 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -39.71 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -444.28m | 5.03bn | 376.00 | -- | 5.74 | -- | -- | -23.08 | -23.08 | 0.00 | 41.13 | 0.00 | -- | -- | 0.00 | -62.81 | -62.09 | -73.92 | -74.81 | -- | -- | -- | -- | 9.39 | -- | 0.1201 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| BridgeBio Pharma Inc | 218.60m | -538.26m | 5.24bn | 550.00 | -- | -- | -- | 23.98 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 5.48bn | 927.00 | -- | 18.48 | -- | 7.06 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Organon & Co | 6.35bn | 1.05bn | 5.49bn | 10.00k | 5.23 | 113.69 | 4.25 | 0.8643 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Cytokinetics, Inc. | 3.75m | -530.60m | 5.56bn | 423.00 | -- | -- | -- | 1,481.39 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 5.64bn | 373.00 | 18.32 | 31.68 | 14.06 | 6.53 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
Data as of May 31 2024. Currency figures normalised to Apellis Pharmaceuticals Inc's reporting currency: US Dollar USD
55.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Mar 2024 | 15.06m | 12.42% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 11.36m | 9.37% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 11.11m | 9.16% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.37m | 7.73% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.88m | 4.03% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 4.61m | 3.80% |
| Jennison Associates LLCas of 31 Mar 2024 | 3.24m | 2.67% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.91m | 2.40% |
| Octagon Capital Advisors LPas of 31 Mar 2024 | 2.81m | 2.32% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.40m | 1.98% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
